Another deputy general manager of a pharmaceutical company, join the resignation team! On November 2, Sailon Pharmaceutical issued an announcement on the resignation of the company's deputy general manager, Mr.
Tong Yan, the company's deputy general manager, applied to resign from the position of the company's deputy general manager due to personal reasons, after the resignation, Mr.
Tong Yan will not hold any position
in the company and its subsidiaries.
The company's 2022 third quarterly report shows that the main revenue during the reporting period was 193 million yuan, a year-on-year increase of 4.
0%; the net profit attributable to the parent was 1.
697 million yuan, a year-on-year decrease of 85.
62%; Non-net profit - 7.
1253 million yuan, down 1027.
53% year-on-year; In the third quarter of 2022, the company's main revenue in a single quarter was 61.
4714 million yuan, a year-on-year increase of 9.
0%; The net profit attributable to the parent in a single quarter was 645,400 yuan, a year-on-year decrease of 72.
94%; Non-net profit deducted in a single quarter - 2.
4372 million yuan, a year-on-year decrease of 1269.
27%; The debt ratio is 34.
69%, the financial expense is 3.
807 million yuan, and the gross profit margin is 60.
19%.
According to the data, Sailon Pharmaceutical is a modern pharmaceutical enterprise integrating R&D, production, marketing and technical services of pharmaceutical intermediates, APIs and preparations, and its main products cover cardiovascular and cerebrovascular, nervous, digestive system, proton pump inhibitors, anti-infective drugs, anti-bleeding drugs, analgesics and other fields
.
Judging from public information, since the beginning of this year, there are not a few deputy general managers of pharmaceutical companies who have left, and since October, a number of deputy general managers of pharmaceutical companies have left
.
On October 31, the deputy general managers of a number of pharmaceutical companies announced their resignation, and Dafo Pharmaceutical issued an announcement that Liu Zhanfeng, the deputy general manager in charge of (production) of the company, resigned due to personal reasons; Fu'an Pharmaceutical announced that Mr.
Xu Peng applied to resign from the position of deputy general manager of the company due to personal reasons; Celi Medical announced that Mr.
Liu Feng, deputy general manager of the company, resigned from the position of deputy general manager of the company due to personal reasons; Mr.
Sun Haifeng of Rejing Bio applied to resign as deputy general manager due to personal reasons
.
ON OCTOBER 25, SHANGHAI XUTAI PHARMACEUTICAL ISSUED AN ANNOUNCEMENT THAT MR.
MAOJIAN GU, DEPUTY GENERAL MANAGER OF THE COMPANY, APPLIED TO RESIGN FROM THE POSITION OF
DEPUTY GENERAL MANAGER OF THE COMPANY DUE TO AGE.
AFTER RESIGNING AS DEPUTY GENERAL MANAGER, MR.
MAOJIAN GU WILL CONTINUE TO SERVE AS A DIRECTOR AND OTHER POSITIONS
IN THE COMPANY.
On October 19, Harbin Pharmaceutical announced that Mr.
Lu Chuanyou resigned from the position of
deputy general manager of the company due to retirement reasons.
On October 10, Hengrui Pharmaceutical announced the change of executives, and Tao Weikang, deputy general manager of the company, resigned due to personal reasons, after resignation, Tao Weikang will no longer hold any position in the company, and the relevant work he is responsible for has been handed over
.
On the same day, He Feng was appointed as the deputy general manager of Hengrui Pharmaceutical, who will undertake the new drug research and development and R&D management of
Shanghai Hengrui R&D Center.
It is reported that He Feng has worked at Bristol-Myers Squibb, Novartis and AbbVie, engaged in the research and development of innovative drugs in the field of
viruses, cancer, kidney diseases and other diseases.
From the perspective of the reasons for the departure of pharmaceutical executives, personal reasons account for the majority
.
Why do pharmaceutical executives leave for personal reasons? Some analysts pointed out that the departure of senior executives in the pharmaceutical industry is partly due to personal career development considerations, and more reflects the impact of changes in the industry policy environment and internal structure adjustment of enterprises on executives, reflecting the trend of transformation and upgrading, change innovation and accelerated flow of talents in China's pharmaceutical industry
.
Industry insiders said that in recent years, with the normalization of centralized procurement, drug price reduction has become a general trend, coupled with the promotion of new medical reform policies such as medical insurance fee control and consistency evaluation, the performance of pharmaceutical companies is under obvious pressure, business adjustment is accelerating, and the corresponding executives may also be accompanied by changes, or have their own new considerations
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
